Sinocelltech Group Ltd (688520)

Currency in CNY
41.85
-1.40(-3.24%)
Closed·
688520 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
41.8243.77
52 wk Range
34.6189.04
Key Statistics
Bid/Ask
41.84 / 41.85
Prev. Close
43.25
Open
43.21
Day's Range
41.82-43.77
52 wk Range
34.61-89.04
Volume
2.65M
Average Volume (3m)
3.07M
1-Year Change
16.769%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688520 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.00
Upside
+17.08%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Sinocelltech Group Ltd Company Profile

Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease. The company was founded in 2002 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.

Employees
2277
Market
China

Compare 688520 to Peers and Sector

Metrics to compare
688520
Peers
Sector
Relationship
P/E Ratio
−64.6x−6.8x−0.6x
PEG Ratio
0.07−0.010.00
Price/Book
−386.6x3.8x2.6x
Price / LTM Sales
9.9x12.1x3.4x
Upside (Analyst Target)
17.1%49.8%44.4%
Fair Value Upside
Unlock−6.1%6.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 49.00
(+17.08% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Oct 30, 2025
EPS / Forecast
-0.38 / --
Revenue / Forecast
339.86M / --
EPS Revisions
Last 90 days

688520 Income Statement

FAQ

What Is the Sinocelltech Group (688520) Stock Price Today?

The Sinocelltech Group stock price today is 41.85

What Stock Exchange Does Sinocelltech Group Trade On?

Sinocelltech Group is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for Sinocelltech Group?

The stock symbol for Sinocelltech Group is "688520."

What Is the Sinocelltech Group Market Cap?

As of today, Sinocelltech Group market cap is 18.64B.

What Is Sinocelltech Group's Earnings Per Share (TTM)?

The Sinocelltech Group EPS (TTM) is -0.64.

When Is the Next Sinocelltech Group Earnings Date?

Sinocelltech Group will release its next earnings report on Apr 22, 2026.

From a Technical Analysis Perspective, Is 688520 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sinocelltech Group Stock Split?

Sinocelltech Group has split 0 times.

How Many Employees Does Sinocelltech Group Have?

Sinocelltech Group has 2277 employees.

What is the current trading status of Sinocelltech Group (688520)?

As of Jan 30, 2026, Sinocelltech Group (688520) is trading at a price of 41.85, with a previous close of 43.25. The stock has fluctuated within a day range of 41.82 to 43.77, while its 52-week range spans from 34.61 to 89.04.

What Is Sinocelltech Group (688520) Price Target According to Analysts?

The average 12-month price target for Sinocelltech Group is CNY49.00, with a high estimate of CNY55 and a low estimate of CNY43. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +17.08% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.